© 2026 MergersCorp M&A International.
© 2025 MergersCorp M&A International is a global brand operating through a number of professional firms and constituent entities (“Members”) located throughout the world to provide Investment Banking, Corporate Finance, and Advisory Services and other client-related professional services. The Member Firms (“Members”) are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit our Disclaimer: https://mergerscorp.com/disclaimer. MergersCorp M&A International's franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited, a UK Company with its registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
MergersCorp M&A International provides strategic business advisory services, including preparing companies for growth and capital access. Through partnerships with licensed investment bankers, clients can access tailored capital-raising solutions.
U.S. Investment Banking Securities transactions are exclusively conducted by Spektrum Capital Advisors LLC, a Registered Representative of, and Securities Products offered through, BA Securities, LLC, a FINRA-registered broker-dealer. Check the background of investment professionals associated with this site on Broker Check.
Founded 11 years ago, the Company operates an end-to-end technology ecosystem for the execution of commercial programs in the pharmacy channel, connecting laboratories, pharmacies, and healthcare professionals through proprietary platforms (CRM, validator, and point-of-sale operational integration). The Company has built a strong market position and is currently a leading player in its segment.
The business model is scalable and proven, with over 5.5 million vouchers issued and a significant nationwide pharmacy presence, supported by a well-established network of ecosystem players and integrations with corporate systems.
Over the past 12 months, the Company has significantly accelerated its growth, achieving a CAGR of over 200% over the last three years, while maintaining high revenue recurrence and attractive margins — with clear upside potential through regional expansion and adjacent channels.
Market potential
The Digital Health market in Latin America is valued at USD 17B in 2024, with a strong projection to reach USD 58.8B by 2030. This growth is driven by rising healthcare costs, a shift toward patient-centric care, increasing demand for real-time data analytics and regulatory compliance, and the impact of generative AI — which is projected to increase healthcare worker productivity by up to 40%.
Within this landscape, the Health & Wellness sector in Latin America is expected to grow to USD 337M by 2034, highlighting a specific high-growth niche for the Company’s platform.
TAM
Includes Digital Health, Pharma Marketing, and health eCommerce
USD 30–40B in Latin America
SAM
Represents the segment accessible by geography and business model — approximately 30% of TAM
USD 9–12B (estimated)
SOM
The Company is currently in an active capture phase, targeting a significant market share within the next 3–5 yearsKey differentiators
| Differentiator | Description |
|---|---|
| Brand Awareness in the Health & Wellness Industry | The Company has 11 years of market presence and holds a dominant position in its segment. The leadership team is composed of founders with over 30 years of experience in the pharmaceutical and healthcare industries. |
| Proprietary B2B SaaS Platform & End-to-End Solution | The Company operates a fully in-house technology suite with complete traceability. This infrastructure centralizes and aggregates all data generated during program execution, creating a high-value strategic data asset. |
| Proven High-Profitability Model | The business model is characterized by high recurring revenue and strong EBITDA margins, ensuring long-term financial stability and scalability. |
| World-Class Client Portfolio & Consolidated Ecosystem | The Company maintains a strong market position with Tier 1 global clients and very low churn rates. It operates a robust, fully integrated ecosystem aligned with the corporate systems of laboratories, distributors, and pharmacies. |
| Proven Operational Traction & Accelerated Growth | A highly validated business model with over 5.5 million vouchers issued and an active network that delivered +280% year-over-year revenue growth in the last year. |
| Unique Vertically Integrated Solution | The only regional platform offering full vertical integration (from medical prescription to financial reimbursement) combined with horizontal segmentation tailored to multiple business use cases. |
© 2025 MergersCorp M&A International is a global brand operating through a number of professional firms and constituent entities (“Members”) located throughout the world to provide Investment Banking, Corporate Finance, and Advisory Services and other client-related professional services. The Member Firms (“Members”) are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit our Disclaimer: https://mergerscorp.com/disclaimer. MergersCorp M&A International's franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited, a UK Company with its registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
MergersCorp M&A International provides strategic business advisory services, including preparing companies for growth and capital access. Through partnerships with licensed investment bankers, clients can access tailored capital-raising solutions.
U.S. Investment Banking Securities transactions are exclusively conducted by Spektrum Capital Advisors LLC, a Registered Representative of, and Securities Products offered through, BA Securities, LLC, a FINRA-registered broker-dealer. Check the background of investment professionals associated with this site on Broker Check.
This website is operated by MergersUS Inc a US Corporation with registered office at





Description
Founded 11 years ago, the Company operates an end-to-end technology ecosystem for the execution of commercial programs in the pharmacy channel, connecting laboratories, pharmacies, and healthcare professionals through proprietary platforms (CRM, validator, and point-of-sale operational integration). The Company has built a strong market position and is currently a leading player in its segment.
The business model is scalable and proven, with over 5.5 million vouchers issued and a significant nationwide pharmacy presence, supported by a well-established network of ecosystem players and integrations with corporate systems.
Over the past 12 months, the Company has significantly accelerated its growth, achieving a CAGR of over 200% over the last three years, while maintaining high revenue recurrence and attractive margins — with clear upside potential through regional expansion and adjacent channels.
Market potential
The Digital Health market in Latin America is valued at USD 17B in 2024, with a strong projection to reach USD 58.8B by 2030. This growth is driven by rising healthcare costs, a shift toward patient-centric care, increasing demand for real-time data analytics and regulatory compliance, and the impact of generative AI — which is projected to increase healthcare worker productivity by up to 40%.
Within this landscape, the Health & Wellness sector in Latin America is expected to grow to USD 337M by 2034, highlighting a specific high-growth niche for the Company’s platform.
TAM
Includes Digital Health, Pharma Marketing, and health eCommerce
USD 30–40B in Latin America
SAM
Represents the segment accessible by geography and business model — approximately 30% of TAM
USD 9–12B (estimated)
SOM
The Company is currently in an active capture phase, targeting a significant market share within the next 3–5 yearsKey differentiators
Basic Details
Target Price:
$ 0
Gross Revenue
$1,700,000
EBITDA
$1,020,000
Business ID:
L#20261027
Country
Argentina
Detail